Skip to main content
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

More about this publication?
Volume 7, Number 1, 2007

Addendum

Author Index To Volume 6
pp. i-iii(3)
Author: Publishers

Favourites:
ADD

Subject Index To Volume 6
pp. iv-x(7)
Author: Publishers

Favourites:
ADD

Articles

Favourites:
ADD

Costimulation, Coinhibition and Cancer
pp. 15-30(16)
Authors: Inman, Brant A.; Frigola, Xavier; Dong, Haidong; Kwon, Eugene D.

Favourites:
ADD

Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
pp. 31-40(10)
Authors: Muller, Alexander J.; Prendergast, George C.

Favourites:
ADD

Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
pp. 41-53(13)
Authors: Horna, Pedro; Sotomayor, Eduardo M.

Favourites:
ADD
Favourites:
ADD

Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer
pp. 71-77(7)
Authors: Nefedova, Yulia; Gabrilovich, Dmitry I.

Favourites:
ADD

Free Content Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
pp. 79-89(11)
Authors: Kanodia, Shreya; Fahey, Laura M.; Kast, W. Martin

Favourites:
ADD

Small Molecule Inhibitors of Stat3 Signaling Pathway
pp. 91-107(17)
Authors: Deng, Jinxia; Grande, Fedora; Neamati, Nouri

Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content